57-Year-Old Woman Presented for Screening Mammography: Digital, A, and tomosynthesis, B, craniocaudal images showed 1.8 cm asymmetry (arrows) lateral left breast categorized as BI-RADS 0. C, Ultrasound left breast evaluation revealed normal fibroglandular tissue (arrow) believed to correlate with mammographic finding. D, Asymmetry effaced on rolled lateral craniocaudal imaging. Metallic BB marker noted at 12 o’clock position, anterior depth. Final assessment BI-RADS 1. Image courtesy of ARRS

57-Year-Old Woman Presented for Screening Mammography: Digital, A, and tomosynthesis, B, craniocaudal images showed 1.8 cm asymmetry (arrows) lateral left breast categorized as BI-RADS 0. C, Ultrasound left breast evaluation revealed normal fibroglandular tissue (arrow) believed to correlate with mammographic finding. D, Asymmetry effaced on rolled lateral craniocaudal imaging. Metallic BB marker noted at 12 o’clock position, anterior depth. Final assessment BI-RADS 1. Image courtesy of ARRS


January 17, 2022 — According to an article in ARRS’ American Journal of Roentgenology (AJR), radiologists should consider performing ultrasound (US) first for digital breast tomosynthesis (DBT)-recalled noncalcified masses.

“Omitting diagnostic mammography when US is negative has a low false-negative rate,” wrote lead researcher Jessica H. Porembka, M.D., from the University of Texas Southwestern Medical Center in Dallas. Noting that US alone is effective in diagnosing noncalcified masses recalled on screening tomosynthesis, “for asymmetries,” she explained further, “diagnostic mammography may be best without the need for additional US, while architectural distortions still warrant diagnostic mammography and US.”

Per the protocol of Porembka et. al’s HIPAA-compliant, IRB–approved prospective study, 399 women (mean age, 60 years) recalled for noncalcified lesions from screening DBT underwent initial diagnostic US from July 2017 to June 2019. Imaging decisions—determined via BI-RADS assessments and management recommendations, biopsy outcomes, and follow-up—were recorded using case reports filed on the day of the diagnostic evaluation.

Ultrasound alone without mammography adequately completed the diagnostic evaluation of 71.2% (306/430) of noncalcified lesions recalled from screening tomosynthesis, 93.7% (178/190) of recalled masses, and diagnosed 92.1% (35/38) of cancers, yielding a sensitivity of 94.9% for cancer diagnosis.

“A large number of screening tomosynthesis–detected noncalcified masses may be further evaluated with ultrasound alone, without compromising diagnostic sensitivity,” the authors of this AJR article reiterated.

For more information: www.arrs.org


Related Content

News | Women's Health

Sept. 15, 2025 — GE HealthCare has launched the Voluson Performance series, the latest addition to its women’s health ...

Time September 15, 2025
arrow
News | Mammography

Sept. 3, 2025 — According to ARRS’ American Journal of Roentgenology (AJR), a commercial artificial intelligence (AI) ...

Time September 09, 2025
arrow
News | Ultrasound Imaging

Sept. 4, 2025 — Ultrasound AI recently announced that the United States Patent and Trademark Office has issued U.S ...

Time September 05, 2025
arrow
News | Mammography

Aug. 19, 2025 — According to the latest study from BCC Research, the "Global Mammography Equipment Markets" is projected ...

Time August 20, 2025
arrow
News | Mammography

Aug. 19, 2025 — Calidar, Inc., a start-up in precision diagnostic imaging formed out of Duke University, recently ...

Time August 19, 2025
arrow
News | Women's Health

June 23, 2025 — Susan G. Komen, the world’s leading breast cancer organization, recently announced it is awarding $10.8 ...

Time June 23, 2025
arrow
Feature | Women's Health | Christine Murray

In breast cancer detection, speed and accuracy are more than clinical goals – they can significantly increase chances ...

Time June 17, 2025
arrow
News | PET Imaging

May 30, 2025 — GE HealthCare recently announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) ...

Time May 30, 2025
arrow
News | Imaging Software Development

May 27, 2025 — DeepLook Medical, a company advancing medical imaging through visual enhancement technology, recently ...

Time May 28, 2025
arrow
News | Mammography

April 29, 2025 — iCAD, a global provider of clinically proven AI-powered cancer detection solutions, has announced a ...

Time April 29, 2025
arrow
Subscribe Now